These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 1862786)

  • 1. Treatment of heroin addicts using buprenorphine.
    Kosten TR; Morgan C; Kleber HD
    Am J Drug Alcohol Abuse; 1991 Jun; 17(2):119-28. PubMed ID: 1862786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of buprenorphine for the treatment of opioid dependence.
    Johnson RE; Fudala PJ
    NIDA Res Monogr; 1992; 121():120-41. PubMed ID: 1383825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
    Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
    Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical trial of buprenorphine: I. Comparison with methadone in the detoxification of heroin addicts. II. Examination of its opioid blocking properties.
    Bickel WK; Johnson RE; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR
    NIDA Res Monogr; 1987; 76():182-8. PubMed ID: 2449618
    [No Abstract]   [Full Text] [Related]  

  • 5. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation.
    Collins ED; Horton T; Reinke K; Amass L; Nunes EV
    J Subst Abuse Treat; 2007 Mar; 32(2):167-75. PubMed ID: 17306725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between plasma cortisol levels, withdrawal symptoms and craving in abstinent and treated heroin addicts.
    Nava F; Caldiroli E; Premi S; Lucchini A
    J Addict Dis; 2006; 25(2):9-16. PubMed ID: 16785214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
    Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
    J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heroin detoxification with a single high dose of buprenorphine.
    Kutz I; Reznik V
    Isr J Psychiatry Relat Sci; 2002; 39(2):113-9. PubMed ID: 12227226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone.
    Negus SS
    J Pharmacol Exp Ther; 2006 May; 317(2):711-23. PubMed ID: 16456085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.
    Jagsch R; Gombas W; Schindler SD; Eder H; Moody DE; Fischer G
    Addict Biol; 2005 Dec; 10(4):365-71. PubMed ID: 16318959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance.
    Calsyn DA; Malcy JA; Saxon AJ
    J Subst Abuse Treat; 2006 Mar; 30(2):159-63. PubMed ID: 16490679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
    Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
    Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients.
    Vigezzi P; Guglielmino L; Marzorati P; Silenzio R; De Chiara M; Corrado F; Cocchi L; Cozzolino E
    J Subst Abuse Treat; 2006 Jul; 31(1):3-7. PubMed ID: 16814005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonidine and opiate receptor antagonists in the treatment of heroin addiction.
    Gerra G; Marcato A; Caccavari R; Fontanesi B; Delsignore R; Fertonani G; Avanzini P; Rustichelli P; Passeri M
    J Subst Abuse Treat; 1995; 12(1):35-41. PubMed ID: 7752296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study.
    Threlkeld M; Parran TV; Adelman CA; Grey SF; Yu J
    Am J Addict; 2006; 15(2):186-91. PubMed ID: 16595358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine dosing regime in the management of out-patient heroin withdrawal.
    Lintzeris N
    Drug Alcohol Rev; 2002 Mar; 21(1):39-45. PubMed ID: 12189003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new approach to preventing relapse in opiate addicts: a psychometric evaluation.
    Grüsser SM; Thalemann CN; Platz W; Gölz J; Partecke G
    Biol Psychol; 2006 Mar; 71(3):231-5. PubMed ID: 16046046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine in opiate withdrawal: a comparison with clonidine.
    Nigam AK; Ray R; Tripathi BM
    J Subst Abuse Treat; 1993; 10(4):391-4. PubMed ID: 8257551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy.
    Messinis L; Lyros E; Andrian V; Katsakiori P; Panagis G; Georgiou V; Papathanasopoulos P
    Hum Psychopharmacol; 2009 Oct; 24(7):524-31. PubMed ID: 19650155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regarding naltrexone for probationers and parolees.
    Stancliff S
    J Subst Abuse Treat; 2007 Mar; 32(2):217-8; author reply 218-9. PubMed ID: 17306730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.